Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Hang Seng TECH Index ETF vs Organon & Co. Common Stock — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $11.52 (market cap $46.22M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 78.3× KraneShares Hang Seng TECH Index ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while KraneShares Hang Seng TECH Index ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Hang Seng TECH Index ETF for 44 Days and Organon & Co. Common Stock for 0 Days on average.
| KTEC | OGN | |
|---|---|---|
Market Cap | $46.22M | $3.62B |
Volume | 22,698 | 2,892,999 |
Sector | Sector/Thematic | Health |
52-Week High | $18.36 | $13.81 |
52-Week Low | $11.41 | $5.70 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KTEC trades at $11.61 with no recent price movement. The stock shows bearish technical signals with 15 sell indicators versus 2 buy signals. Fundamentally, the company reported $120.04M revenue in 2016 with a net loss of $697K, though cash flow improved to positive $2.77M. Recent news highlights China's AI competition potentially benefiting tech ETFs like KTEC.
KTEC faces mixed prospects with improving cash flow but inconsistent profitability. The bearish technical outlook and volatile earnings history suggest caution, though exposure to AI sector growth through ETF positioning offers potential upside. Key risks include competitive pressures and execution challenges in maintaining positive momentum.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
